메뉴 건너뛰기
British Journal of Ophthalmology
Volumn 92, Issue 5, 2008, Pages 667-668
Predicted biological activity of intravitreal VEGF Trap
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; THROMBIN RECEPTOR ACTIVATING PEPTIDE; VASCULOTROPIN;
EID: 43649083100     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.134874     Document Type: Article
Times cited : (355)
References (10)
  • 1
    • 11144239923 scopus 로고    scopus 로고
    • Pegaptanib for neovascular age-related macular degeneration
    • Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
    • (2004) N Engl J Med , vol.351 , pp. 2805-2816
    • Gragoudas, E.S.1    Adamis, A.P.2    Cunningham Jr, E.T.3
  • 2
    • 33749445317 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
    • (2006) N Engl J Med , vol.355 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3
  • 3
    • 33749451356 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin for age-related macular degeneration
    • Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for age-related macular degeneration. N Engl J Med 2006;355:1432-44.
    • (2006) N Engl J Med , vol.355 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3
  • 4
    • 23044505200 scopus 로고    scopus 로고
    • Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration
    • Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
    • (2005) Ophthalmic Surg Lasers Imaging , vol.36 , pp. 331-335
    • Rosenfeld, P.J.1    Moshfeghi, A.A.2    Puliafito, C.A.3
  • 5
    • 0037401890 scopus 로고    scopus 로고
    • R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier
    • R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195:241-8.
    • (2003) J Cell Physiol , vol.195 , pp. 241-248
    • Saishin, Y.1    Saishin, Y.2    Takahasi, K.3
  • 6
    • 33747874091 scopus 로고    scopus 로고
    • A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration
    • Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522-32.
    • (2006) Ophthalmology , vol.113 , pp. 1522-1532
    • Nguyen, Q.D.1    Shah, S.M.2    Hafiz, G.3
  • 7
    • 13944266313 scopus 로고    scopus 로고
    • Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration
    • Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33.
    • (2005) Invest Ophthalmol Vis Sci , vol.46 , pp. 726-733
    • Gaudreault, J.1    Fei, D.2    Rusit, J.3
  • 8
    • 0032864292 scopus 로고    scopus 로고
    • 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
    • 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-44.
    • (1999) Toxicol Pathol , vol.27 , pp. 536-544
    • Mordenti, J.1    Cuthbertson, R.A.2    Ferrara, N.3
  • 9
    • 34247400587 scopus 로고    scopus 로고
    • Pharmacokinetics of intravitreal bevacizumab (Avastin)
    • Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9.
    • (2007) Ophthalmology , vol.114 , pp. 855-859
    • Bakri, S.J.1    Snyder, M.R.2    Reid, J.M.3
  • 10
    • 36749023451 scopus 로고    scopus 로고
    • Predicted biologic activity of intravitreal bevacizumab
    • Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina 2007;27:1196-200.
    • (2007) Retina , vol.27 , pp. 1196-1200
    • Stewart, M.W.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.